[Rheumatoid arthritis, inflammation, and atherosclerosis]

Area of Science:

• Rheumatology and Cardiovascular Medicine
• Pathophysiology of Atherosclerosis
• Immunology and Vascular Biology

Context:

• Rheumatoid arthritis (RA) patients face a 2-5x higher risk of premature cardiovascular disease (CVD).
• Traditional CVD risk factors are often absent in RA patients, suggesting other mechanisms are at play.
• Inflammation is a shared pathway in both RA pathogenesis and atherosclerosis development.

Purpose:

• To explore the link between systemic inflammation in RA and vascular dysfunction.
• To investigate how RA-associated inflammatory factors contribute to endothelial dysfunction and atherosclerosis.
• To highlight the role of inflammation in the increased CVD morbidity and mortality observed in RA.

Summary:

• Inflammation in RA extends beyond joints, affecting the vessel wall and causing endothelial dysfunction.
• Pro-inflammatory cytokines (e.g., IL-1β, TNF-α), CRP, and adhesion molecules are implicated in RA-related vascular damage.
• Shared mechanisms like matrix metalloproteinases (MMPs) and coagulation factors (e.g., TF, vWF, PAI-1) link RA and cardiovascular disease (CAD).
• Impaired endothelial function is observed in early RA and correlates with cardiovascular prognosis.

Impact:

• Understanding these mechanisms can lead to novel treatment strategies for RA that target cardiovascular risk.
• Anti-inflammatory therapies, such as anti-TNF-α and statins, show potential in improving endothelial function in RA patients.
• Further large-scale clinical trials are needed to confirm if improved endothelial function translates to reduced cardiovascular events in rheumatologic diseases.